source
- Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlookInvestors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by better-than-expected results for newer drugs like Leqembi and Skyclarys.BioPharma Dive · 3mo ago↗ source
- STAT+: Axsome wins FDA nod for Alzheimer’s agitationVinay Prasad's acting replacement, remembering genomics pioneer J. Craig Venter, and more biotech news from The ReadoutSTAT · 3mo ago↗ source
- STAT+: Pharmalittle: We’re reading about obesity drugs and a compounding list, an AstraZeneca setback, and moreThe FDA proposed excluding the active ingredients in popular obesity and diabetes drugs from a list of substances that can be used for compounded versionsSTAT